Fuidi herd management schema

ABSTRACT

The invention is a herd management schema based upon the inventor&#39;s analysis of the natural history of bovine infection due to  Mycobacterium avium  subspecies  paratuberculosis  (Map) and related genomic variants and upon the ability of two distinct Map ELISA tests to sequentially or in parallel determine prior and current Map infection and evidence of active  mycobacterium  replication. Interpretation of the test results are integrated into sequential directives designed to enhance productive retention of infected animals as well as identify animals not previously infected. The sequential utilization of the data guidelines is developed to minimize the adverse economic impact.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No.12/287,822, filed Oct. 15, 2008, now U.S. Pat. No. 8,008,033, thedisclosure of which is hereby incorporated by reference in its entirety,including all figures, tables and amino acid or nucleic acid sequences.

FIELD OF INVENTION

The present invention is a business method/utility patent thatintegrates two types of serum ELISA tests for Mycobacterium aviumsubspecies paratuberculosis (Map) into a herd management schema thatcapitalizes on the natural history of Map infection.

DESCRIPTION OF PRIOR ART

The Disease

National Policy: Mycobacterium avium subspecies paratuberculosis (Map)is the causative agent of a chronic progressive granulomatous disease ofthe gastrointestinal tract, Johne's disease (Clarke 1997; Whitlock1996). The organism is global in its distribution and causes disease inboth wild and domestic herbivores. The granulomatous inflammation leadsto diarrhea, cachexia, and eventual death (Clarke 1997; Raizman 2005).Infection with Map is increasing in prevalence among food-producinganimal globally.

Economic Impact for the Dairy Industry: Estimates of herd prevalenceusing serological screening are comparatively low compared to thenumbers achieved with fecal culture screening. Within large herds, up to40% of cows may be infected (Chiodini 1983). Annual financial loss tothe United States Dairy Industry alone is estimated at $220 million(Otts 1999).

Zoonotic Potential: Animal disease control programs have tended to focuson diseases with major economic impact, trade implication and/orzoonotic potential (Grant 2005). The zoonotic potential of Map may soonovershadow its annual adverse economical impact. In its progression fromsub-clinical infection to disease, Map is introduced into the human foodsupply by virtue of its presence in milk. Map within milk is notadequately destroyed by pasteurization (Ayele 2005; Ellingson 2005;Giese 2000; Grant 2002; Miller 1996; Wuhib 2005),

Mycobacterium bovis is a documented zoonosis (Chiodini 1996;Herman-Taylor 1998). The organism is believed to pass from infectedanimals to man, primarily through oral ingestion of milk. The criticalquestion regarding Map is not whether the organism is a zoonosis, butrather, in its dissemination to humans is Map etiologically linked toCrohn's disease.

A strong circumstantial case is developing which suggests that Map canfunction as a zoonotic pathogen with respect to Crohn's disease(Chiodini 1996; Mishina 1996; Naser 2000; Sechi 2001; Whittington 2000).Naser et al. isolated Map from the milk of two lactating women withCrohn's disease and none from five samples from normal control (Naser2004).

Serum ELISA Mycobacterium Avium Subspecies Paratuberculosis Tests

ELISA Test Sensitivity

Two Map ELISA tests are in current use in the United States. Thecommercial Map ELISA tests, PARACHEK (Prionics, Zurich, Switzerland) andHERDCHEK (IDEXX Laboratories Inc. Westbrook, Me.) are based on thelipoarabinomannan polysaccharide (LAM) or other Map membrane relatedconstituents. The Map strains used for diagnostic testing possess the IS900 DNA insertion sequence. Map polymerase chain reaction (PCR) testsusing primers derived from the IS900 gene sequence are used to conferspecificity to suspected culture isolates. This insertion sequence isthe principle means by which Map is differentiated from othermycobacteria (Sugden, Harris).

While there is a high degree of correlation between both types ofcommercial tests when done on clinically ill (fecal shedding, weightloss and diarrhea) animals, both types of Map ELISA tests fail toidentify a significant number of fecal culture positive animals. Thetests are used to identify negative, suspicious, and positive isolates.In terms of developing overt clinical disease, a sero-positive isolatehas a positive predictive value of 74. A positive commercial Map ELISAtest and/or fecal culture evidence of significant fecal shedding are thecriteria (USDA's advocated policy of test-and-cull) in current use bywhich a decision is reached to remove a given animal from the herd(Harris). No diagnostic significance has been given to transientnon-diagnostic values identified by either of the commercial Map ELISAtests. Despite the use of test-and-cull schema in herd management, theprevalence of Map in dairy herds has progressively increased.Sereologically positive, subclinically infected, as well as diseaseddairy cows have been shown to shed Map into their milk and potentiallyintroduce zoonotic pathogens into the human food chain.

Collins et al. evaluated five antibody detection tests for the diagnosisof bovine paratuberculosis using serum samples from 359 dairy cattle inseven paratuberculosis-free herds and 2,094 dairy cattle in sevenMap-infected dairy herds. Both the PARACHEK and HERDCHEK (IDEXX) ELISAtests done in accordance with manufacturers' instruction and interpretedas prescribed by the kit insert, identified less than 29% of fecalculture positive cows. Linear regression analysis of quantitativeresults showed low correlation co-efficiency. Sockett et al. reportedthe sensitivity of commercial Elisa's for cattle to be 8.9 to 32.1% forlow shedders and 47.1 to 62.9% for midlevel shedders. Sweeney et al.have suggested that commercial Elisa's might have a sensitivity ratelower than 13.5%. McKenna et al. tested sera collected from dairy cowsat slaughter in assessing the agreement with documented infection ofthree commercially available Map ELISA tests which included HERDCHEK andPARACHEK. The investigators found a poor agreement between the threeELISA tests and infected cows. Mycobacteria have been shown to be morereadily identified within feces when the currently commerciallyavailable Map ELISA tests are in their projected positive diagnosticzones (Cocito). The high incidence of false negatives with the PARACHEKand/or HERDCHEK ELISA tests has limited utility to identifying animalswith an advanced disease state. A second concern with the membrane-basedMap ELISA tests is the occurrence of false-positive test results.

Overall, the PARACHEK and HERDCHEK Map ELISA tests suffer from a lack ofsensitivity in identifying animals with positive fecal cultures. Mostclaims of sensitivity have focused upon heavy shedding and/or clinicallydiseased animals. A suspicious or positive test did not necessarilypredict outcome. The quest for antigenic specificity excluded the issueof genetic polymorphism within Mycobaterium avium subsp.paratuberculosis (Map).

A second type of Map ELISA test was developed utilizing primarilyprotoplasm from a Mycobacterium 18 that was initially thought to be Mapbut was later demonstrated to be more Mycobaterium avium than Map.Current data referable to the sensitivity of protoplasmic or wholeorganism antigen-based Map ELISA tests is lacking. While these testsidentify diseased animals, they also produced a significant number ofpositive test results in animals that lacked confirmation by fecalculture or longitudinal clinical assessment. This fact significantlylimited their utilization and virtual abandonment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1—Part I of the FUIDI Herd Management Schema schematically presentsthe sequence of events when a diagnostic serum sample is submitted to aFUIDI certified veterinary diagnostic laboratory. The FUIDI testinvolves two Map ELISA tests that differ in their antigen spectrum andnot completely overlap. Both FUID#1 and FUIDI#2 tests are advocate, butcost considerations make sequential use more likely to be chosen withserum reanalysis with the FUIDI#2 test indicate only when FUIDI#1 hasindicated serological evidence of current or prior significant B-cellstimulation. A negative Map FUIDI#1 test indicates that no evidence ofMap directed B-cell stimulation is detected and the action advocated isto retest the animal annually.

If the FUIDI#1 test is suspicious or positive, the serum sample isretested to assess the probability of active antigen processing. If theFUIDI#2 test is negative, the recommended action is to retest the animalannually and/or after calving.

If a non-diagnostic or low titer is identified by the FUIDI#2 Map ELISAtest, the interpretation is that a low-level ongoing infection ispresent. The vast majority of these animals will achieve immunologicalcontainment of mycobacterium replication. To assess, whether immunecontainment or progression towards disease is likely to ensue, therecommended action is to retest the animal using the FUIDI#1 and #2 MapELISA tests in 3 months. If a diagnostic titer is identified, theinterpretation is of high level mycobacterium replication. While theanimal has about a 1 in 4 chance of achieving immunological containment,such an animal is, more likely than not a high fecal shedder of Map andshould be culled. If a valuable animal or clinical parameter such asbody score and milk/fat production are good, quantitative fecalculturing may provide valuable information for the information decisionmaking.

FIG. 2—Part II of the FUIDI Herd Management Schema. Part II is designedto provide an additional level of monitoring to determine theprobability of immunological containment versus progression of infectiontowards disease for a given animal. Fecal culturing of animals with highdiagnostic FUIDI Test #2 results is reserved for uniquely valuableanimals (bulls, valuable zoo animals) that have been isolated and forwhom enhancement of their immune system is being implemented.

A fecal specimen is obtained for quantity assessment by direct fecalculture or by direct fecal nested or real-time Map polymerase chainreaction (PCR) tests. A negative culture indicates either immunologicalcontainment or sample error. The more probable demonstration indicatesnon-concurrence between serological data and organism shedding andwarrants retesting of subsequent sera using FUIDI#2 Map ELISA test tosee if serum titers decrease. If heavy fecal shedding is confirmed, therecommended action is to cull.

FIG. 3—Part III of the FUIDI Herd Management Schema focuses on animalsthat have had inferred active low level infection as determined theFUIDI #2 Map ELISA test. Production salvage of infected animals withinthis group is a key feature of the FUIDI Herd Management Schema.

The key indicator as to prognosis is the diagnostic readings obtainedupon serial FUIDI#2 testing. If the titer disappears or dropssignificantly, the potential for having Map into the milk, other than bycontamination, is markedly reduced. If the FUIDI#2 titer remainsrelatively comparable, unless the animal's immune system is upregulated,the probability of progression to disease and Map shedding into aretheoretically enhanced. If the titer increases by 0.4 or greater, eventhough not in the test's diagnostic range, the recommended action is tocull.

It should be understood that the examples and embodiments describedherein in FIGS. 1-3 are for illustrative purposes and that variousmodifications or changes in light thereof will be suggested to personsskilled in the art and are to be included within the spirit and purviewof this application or embodiment thereof disclosed herein can becombined with any and/or all other elements or limitations (individuallyor in any combination) or any other invention or embodiment thereofdisclosed herein, and all such combinations are contemplated with thescope of the invention without limitations.

DESCRIPTION OF THE INTELLECTUAL BASIS OF THE INVENTION

Protoplasmic Antigen from Mycobacterium Species: FUIDI 1 (designated as“PTA-11837”) was deposited with American Type Culture Collection (ATCC),P.O. Box 1549, Manassas, Va. 20108, on Apr. 18, 2011. The material hasbeen deposited under conditions that assure that access to the materialwill be available during the pendency of this patent application to onedetermined by the Commissioner of Patents and Trademarks to be entitledthereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposited material willbe available as required by foreign patent laws in countries whereincounterparts of the subject application, or its progeny, are filed.However, it should be understood that the availability of a deposit doesnot constitute a license to practice the subject invention in derogationof patent rights granted by governmental action.

The invention is based upon re-defining existing data concerning MapELISA tests in light of novel information derived by the inventor.

The existing information used was the antigenic base of the currentcommercial Map ELISA tests: the lipoarabinomannan polysaccharide (LAM)and/or related lipoprotein membrane constituents. This information wascombined with the fact that these types of antigens tend to be ofantibodies that are of relatively short duration compared withantibodies elicited by ribosomes and nucleic acid constituents.

Collaborative research done with United States Department ofAgriculture, South Florida Dairy Herd Demonstration Project providesinsight that alter perception of the natural history of Map infection.In a study of Map ELISA titers derived over a 14 month period, it wasnoted that approximately 10-11% of dairy cows would develop transientlow level diagnostic antibodies which would disappear when retested. Theliterature infers the progressive nature of Map.

First, sixty-six sera were obtained from a North Florida dairy herdwhich had a high incidence of clinical disease. All tests were run inaccordance with the manufacturers' specification. Positive and negativecontrols were utilized. Seven sera were identified as being positive byall three tests: six by the PARACHEK test, six by the HERDCHEK test, andseven by a protoplasmic-based ELISA test. The PARACHEK and IDEXX testseach failed to identify a positive sample identified by the other test.The higher the protoplasmic-based ELISA test registered, the greater theprobability that the corresponding PARACHEK and/or HERDCHEK would bepositive. The protoplasmic antigen-based test identified an additional11 cows as having significant titer (14).

In an unpublished study, the FUIDI (a whole organism antigen basesource) and PARACHEK Map ELISA tests were compared in parallel on thesame serum specimen (Table 1-1). In Herd #1 that was reputedly Map-free,the PARACHEK ELISA test did not identify any serum specimens as beingpositive. The FUIDI ELISA test identified 10 animals as being infected.In Herd #2 that had a significant number of seroreactive cows, thePARACHEK ELISA 2 as being positive and 10 as being suspicious. The FUIDIELISA test identified 16 as being positive and 3 as being suspicious.

This observation lead to the comparative use of a Map ELISA test whoseantibody capturing capacity was dictated by LAM and a modified Map ELISAtest (FUIDI) that identified antibodies to the protoplasmic massantigens as well as surface membrane elements.

Significance of Diverging Map ELISA Test Results in Dairy Cows

Johne's disease is a chronic granulomatous disease of the bovinegastrointestinal tract caused by Mycobaterium avium subspeciesparatuberculosis (Map) (1). The adverse economical impact of diseaseglobally is estimated at 1.5 billion dollars annually (2).

The commercial Map ELISA tests have very poor sensitivity in identifyinginfected cows (3,4). Collins et al. evaluated five antibody detectiontests for the diagnosis of bovine paratuberculosis using serum samplesfrom 359 dairy cattle in seven paratuberculosis-free herds and 2,094dairy cattle in seven Map-infected dairy herds (5). Both the PARACHEK(Prionics, Zurich, Switzerland) and HERDCHEK (IDEXX Laboratories Inc.Westbrook, Me.) ELISA tests done in accordance with manufacturers'instruction and interpreted as prescribed by the kit insert, identifiedless than 29% of fecal culture positive cows. Linear regression analysisof quantitative results showed a low correlation co-efficiency. Sockettet al. reported the sensitivity of commercial Elisa's for cattle to be8.9 to 32.1% for low shedders and 47.1 to 62.9% for midlevel shedders(6). Sweeney et al, have suggested that commercial ELISAs might have asensitivity rate lower than 13.5% (7). McKenna et al. tested seracollected from dairy cows at slaughter in assessing the agreement withdocumented infection of three commercially available Map ELISA testswhich included HERDCHEK and PARACHEK. The investigators found a pooragreement between the three ELISA tests and infected cows (8).Mycobacteria have been shown to be more readily identified within feceswhen the currently commercially available Map ELISA tests are in theirprojected positive diagnostic zones (9).

A prior comparison of the IDEXX, PARACHEK and FUIDI Map ELISA #1 testshad shown excellent correlation between the three tests when thediagnostic criteria of either the IDEXX or PARACHEK tests were used toestablish the denominator (12). Seven cows out of 66 cows wereidentified by all three tests: 6 by the PARACHEK test, 6 by the IDEXXtests and 7 by the FUIDI test. The IDEXX and PARACHEK tests each failedto identify a positive serum identified by the other. The FUIDI MapELISA test identified 11 additional dairy cows as being infected withMap. The higher the FUIDI titer, the better the correlation was betweenthe three tests. That is discrepancy between the FUIDI and commercialtests was not simply a case of over-diagnosis was inferred when thePARACHEK and FUIDI Map ELISA tests were tested against 9 sera from cowswith necropsy confirmed Johne's Disease (13). In the PARACHEK Map ELISAtest, four sera demonstrated any activity, but only one was positive andone was suspicious. In the prototype FUIDI test, six were positive. Withthe new diagnostic groupings for the FUIDI test, three would have beenpositive and three would have fallen in the suspicious category.

To achieve the mandated specificity indicative of only Map, the targetantigens of the current commercial Map ELISA tests have had to be basedupon a limit antigenic array such as the lipoarabinomannan or selectedMap surface proteins. The serological response is a partial function ofantigen complexity (10, 11). Different antigens elicit divergent typesof antibodies. Whole organism antigenic utilization elicits an array ofantibodies whose spectrum of reactivity exceeds that induced by subunitsof the organism. By using a modified whole organism, the FUIDI testpresents a significantly broader antigen array.

The purpose of this study is to analyze the possible significance ofidentification of any Map antibody titer by the PARACHEK Map ELISA testin conjunction with the corresponding FUIDI #1 Map titer and comment onthe ramification derived from both tests as they apply to the naturalhistory of bovine Map infection as opposed to Map disease.

Materials and Methods

Study Population:

Infectious Disease Incorporated (IDI) through its strategic partnershipwith the University of Florida College of Veterinary Medicine (UFCVM)was given access to sera and serological data derived from the 2008USDA's Florida Johne's Disease Dairy Herd Demonstration Project (14).The study sera were determined a given cow's serum having been tested bythe State of Florida Diagnostic Laboratory in December of 2006 as wellas February 2008 and its subsequent availability for retesting in 2008.The PARACHEK and FUIDI Map ELISA test results were derived by testingthe same February 2008 serum samples.

PARACHEK Map ELISA Test: The PARACHEK Map ELISA tests were done at theState of Florida Diagnostic Laboratory-Live Oak in accordance to themanufacturer's instructions. Positive and negative controls wereutilized. The test results were forwarded to the USDA's Office inGainesville Fla. A suspicious reading was 0.50 to 0.99. A reading equalto or above one (1) was deemed positive.

Analysis of the PARACHEK Map ELISA data has presumed that the evidencepresented to U.S. Department of Agriculture for commercial acceptanceand certification had to have convincingly demonstrated that the testtruly identifies antibodies specific to Map.

FUIDI Map ELISA #1 Test

The FUIDI Map ELISA test #1 uses primarily a modified antigen arraybased primarily on a Map isolate originally thought to be Map, but laterbeen shown to be more Mycobacterium avium-like. Test sera werepre-absorbed with Mycobacterium pheli. ELISA results were calculatedfrom absorbance at OD 405 nm. Readings less than 1.9 optical densities(OD) were deemed negative; readings between 1.9 and 2.4 were deemed asrequiring close monitoring/suspicious. Readings of 2.5 OD or greaterwere called positive. All FUIDI Map ELISA #1 tests done at UFCVM wererun in triplicate with both positive and negative controls. The testresults were forwarded to the USDA's Office in Gainesville Fla.

Fecal Cultures: Fecal samples were shipped FedEx in coolers with icepacks to the Animal Disease Diagnostic Laboratory at Purdue Universityand processed according to that laboratory's internal protocols.

Data Processing:

The PARACHEK ELISA test results from the 2007 Florida Johne's DiseaseDairy Herd Demonstration Project (testing done Dec. 13, 2006) were madeavailable during the study. Once the final FUIDI Map test results hadbeen submitted to USDA, the 2008 Florida Johne's Disease Dairy HerdDemonstration Project test results were forwarded for comparativeanalysis.

Statistical Analysis:

The random selection of the study sera which lacked specific targetedsubgroups limited meaningful statistical analysis. For relativecomparisons only, likelihood ratios (LR) were constructed for the FUIDIMap ELISA data to lend possible insight as to whether or not a FUIDIpositive test result would predict a previously or concurrently Mapdairy cow with Map specific antibodies. The LRs were calculated asfollows: LR=(number of sera with a positive FUIDI Map ELISA test resultdivided by the number of sera which over approximately 14 months hadbeen shown to have Map specific antibody; the number of positive andsuspicious FUIDI ELISA tests divided by the number of PARACHEK serawhich identified newly developed Map antibodies; the number ofFUIDI-positive sera divided by the number of PARACHEK sera with Mapantibodies at any time.

Results:

Of the 140 sera tested in February of 2008, 103 had been tested onDecember of 2006. In December of 2006, 10 of the 103 sera test had anytiter as measured by the PARACHEK Map ELISA test. Two werePARACHEK-positive and one serum was identified as beingsuspicious/inconclusive.

When reanalyzed in 2008, no data was available on one of thePARACHEK-positive animals (#2920; however, a strong positive titer wasrecorded in the FUIDI test (Table 2). One low PARACHEK tittered cow(#1011) had its ELISA test values moved into from 0.08 into the test'spositive zone (2.38). Five previously low tittered sera became totallynegative.

Two cows had PARACHEK reading in the test's positive range. No follow-upPARACHEK test was done for cow #2920; however the high positive FUIDIreading is consistent with a continued high level of antigen processing.The other PARACHEK positive cow (#2290 exhibited a very significant dropin demonstrable Map antibodies (1.32 to 0.050). The suspicious PARACHEKserum similarly fell out of its diagnostic zone (0.72-0.02).

The remaining cow's serum maintained a persistent low Map antibodypresence. Of these 11 sera which had any Map antibodies by the PARACHEKMap ELISA, 4 were positive and 3 were suspicious as determined by theFUIDI Map ELISA. The LR for the sera deemed positive in the FUIDI ELISAtest is 0.40. If the suspicious and positive FUIDI results are combined,the FUIDI ELISA test's LR becomes 0.70.

Nine out of the 93 cows without prior Map antibodies in December 2006developed low levels of Map antibodies when tested in February of 2008(Table 3). The corresponding FUIDI tests were positive in two cases andsuspicious in two others. The combined FUIDI positive and suspiciousresults create a LR of 0.56.

Table 4 reflects the shift of emphasis from PARACHEK directedcomparisons to FUIDI directed comparisons. The FUIDI Map ELISA#1 testwas positive in 12 instances. The presence of prior or concurrent Mapantibodies as demonstrated by the PARACHEK Map ELISA test was identifiedin 8 instances.

Of the 21 animals postulated as requiring added surveillance/monitoring(suspicious category), six had prior or current identification ofspecific Map antibodies as identified by the PARACHEK ELISA and 4 of the21 cows had a positive fecal culture. Combining the two criteria, priordemonstration of Map specific antibodies by the PARACHEK test andpositive fecal cultures, approximately ⅓ of the cows in the FUIDIsuspicious category had evidence of Map infection.

Two cows out of the 37 cows not previously tested in December of 2008developed low levels Map antibody titer as determined by the PARACHEKtest. For one of the two cows, the corresponding FUIDI test waspositive.

Eleven cows had Map recovered from a fecal specimen (Table 5). Of the 11Map positive fecal cultures, the PARACHEK test identified one as beingpositive in February 2008 (LR=0.09) The FUIDI identified in 2008 one asbeing positive and four as being suspicious (combined LR=0.36).

Discussion:

The primary focus of the comparison of the PARACHEK and FUIDI Map ELISA#1 tests was not to document that one test is necessarily better thanthe other, but rather to point out that these two ELISA tests do notnecessarily convey the same information applicable to the naturalhistory of bovine Map infection. When the 2008 suspicious and positiveFUIDI Map ELISA #1 test results are compared with sera that, in either2007 or 2008, a sufficiently high correlation can be shown supportingthe contention that the cows so identified as having any Map antibodytiter in the PARACHEK test have experience infection with Map. Theoverlapping correlation over time between a positive FUIDI ELISA titerand any titer PARACHEK ELISA test result strengthens the contention thatany antibodies identified by the PARACHEK Map ELISA test are specificMap antibodies.

The FUIDI Map ELISA #1 was selected for development and testingpredicated upon its ability to identify Map-like mycobacteria as well asMap. The rational for this decision was the contention that Maps strainsevolved from a Mycobacteria avium base and its genomic differentiationhas resulted in genomic polymorphism of mycobacterium stains that arecapable of inducing Johne's disease (14-24).

The FUIDI Map ELISA #1 test results can be challenged by the contentionthat they also identify environmental mycobacteria. Osterstock et al.parenterally immunized beef calves with Mycobacterium celatinum, M.scrofulaceum, M. intracellulare, and M. avium subspecies avium (25).False-positive ELISA tests were recorded with both commercial Map ELISAtests currently used in the United States. The authors contended thatenvironment mycobacteria were responsible for some of the false positivetests previously observed in beef cattle. What they more probablydemonstrated IS900 insertion sequence may share antigenic elements withselected environmental mycobacteria. The production of ELISA-positiveantibodies directed against an environmental mycobacterium had requiredthe subcutaneous injection with adjuvant of large numbers of organisms.In order to achieve a comparable PARACHEK-positive antibody response innature would require organism internalization, antigen processing, and alarge antigen mass: more specifically defined, infection.

In contrast to intracellular mycobacteria, the vast majority ofpathogenic bacteria undergo complete organism elimination. In the courseof disease, extremely high titers of antibodies directed againstlipopolysaccharide and lipoprotein membrane components are produced;however their detection is relatively short-lived. The explanationadvanced to account for disappearance of specific antibody titer hasbeen that the eliciting antigenic templates are no longer available(27,28).

The appearance and disappearance of PARACHEK identified Map antibodiesappears to be a direct function of the elicitor antigenic component usedto develop the test. The PARACHEK Map ELISA test appears to becontingent upon continued processing of its antigenic elicitor forantibody production.

The loss of PARACHEK Map detectable antibodies implies that the host'simmune response has achieved immunological governance. Mycobacteria,like M. tuberculosis, despite recovery, do not undergo completeelimination from the body. Evidence of an immune response persists yearsafter the initial system introduction of the organism into the hostanimal (26). Reactivation of organism replication can occur when thehost animal's immune system has undergone significant compromise (26).

By itself, the interpretation of data implying immune governance couldbe open to debate. What the FUIDI Map ELISA #1 data does lendsubstantial credence to the contention that these animals which havelost PARACHEK titer have had or are experiencing on a non-detectablelevel by the PARACHEK test infection with Map.

Epidemiologically, the small fragments of data relative to the loss ofantibody titer directed against surface component of Map imply that anumber of dairy cows infected with Map may achieve immunologicalgovernance. Fifty percent of the 10 cows with any Map antibodies hadtheir titer in the PARACHEK test revert to a non-detectable titer uponretesting. Expansion to observations to an analysis of 602 dairy cowsfrom which the 103 study sera were derived reveals that 46 of the 62cows (75.8%) with previously identified Map antibodies lost all titerupon retesting.

A significant bias in the PARACHEK Map antibody group was the relativeabsence of animal identified by testing as being suspicious or positive.The herd's management schema dictated that serologically positive orsuspicious cows, cows with significant fecal shedding, and/or cows withclinical signs be systematically culled from the herd. Nevertheless,three such animals were present in the study population: 2 testPARACHEK-positive and 1 PARACHEK-suspicious. Of the twoPARACHEK-positive cows: one is inferred to have had a high level ofantigen processing by the corresponding high positive FUIDI titer. Theother positive cow had her PARACHEK titer drop from 1.32 to 0.05.Similarly, the suspicious cow's PARACHEK titer fell from 0.72 to 0.02.In both cases, the corresponding FUIDI titer was non-diagnostic.

The FUIDI Map ELISA #1 test appears to better identify the probabilityof either significant prior or current Map infection. The FUIDIantigenic base is constituted by a broad array immunogens, some of whichare theorized to persist along with evidence of specific cell-mediatedimmunity. Of the 10 sera with any positive antibody titer as determinedby the PARACHEK done in December 2006, the FUIDI ELISA test was positivefor 4 and suspicious for another 3, giving a combined LR of 0.7. Ninepreviously negative PARACHEK sera developed low levels of Map specificantibodies. The corresponding FUIDI titer was positive in 2 cases andsuspicious in 2 of the 9 cases giving the combined group a LR of 0.56.

Of the 17 positive sera identified by the FUIDI Map ELISA #1 test, 6identified cows that had or had evidence as specific Map antibodies asdetermined by the PARACHEK Map ELISA test (LR=0.35). If corrected toinclude a cow with positive fecal cultures the LR becomes 0.40.

Of the 21 suspicious FUIDI sera, 6 cows had or had had evidence of Mapantibodies as determined by the PARACHEK Map ELISA test (LR=0.29). Twocows with no detectable Map antibodies, but suspicious in the FUIDI testwere present.

For the cows with no detectable Map antibodies in 2007 and 2008, thereis no way of accessing if in years prior to 2007 that they had notacquired Map infection with subsequent acquisition of immune governancewhich may account for some of the false positive FUIDI titers recorded.

The PARACHEK Map test appears to identify ongoing Map membrane antigenprocessing. The magnitude of the titer indicates the probability offuture disease induction; however a diagnostic test does not necessarilypredict future outcome. One PARACHEK-positive cow and one cow with asuspicious titer in 2007 when retested had insignificant residual titerin 2008.

From the Map ELISA test comparisons, any demonstration of Map specificantibodies by the PARACHEK Map ELISA test indicates systemic antigenicprocessing. The FUIDI-positive Map ELISA #1 test appears to identifyboth underlying as well as current Map infection. Like the PARACHEK testdata, the FUIDI #1 test results cannot predict outcome, justprobability. The FUIDI Map ELISA #1 test's utility appears to lie in itsability to better identify a subpopulation that could profit from moreintensive monitoring.

From a parallel use of both ELISA tests, a better perception of thenatural history of Map bovine infection is likely to emerge.

What is established from the cited data is that the transient positivetiters identified by a LAM-based ELISA test were indicative of their Mapspecific antibodies. Their disappearance inferred that like, the humanmodel, Mycobacterium tuberculosis, infection and immune capture are acommon phenomenon and progression of infection to Johne's disease is arelative rarity.

The positive titers identified by protoplasmic antigen based tests arenot false-positives but, with reasonable probability, identified priorMap infection (comparable to a positive PPD reaction to tuberculin), andthe so-called false-positive tests observed with LAM-based Map ELISAtests are animals which subsequently achieved immune capture of theorganism.

The novelty of the invention is how these new observations are used tocreate a comprehensive herd management schema which will allow domesticanimal producers to better manage Map within their herd by retaininginfected animals which by other criteria would be culled.

Prior to the development of the FUIDI Herd Management Schema, the goldstandard was annual serological testing of animals using either thePARACHEK or HERDCHEK Map ELISA tests and/or fecal culture to determineif an animal should be removed from a herd for production considerationsand/or for constituting a greater threat of introducing Map into thehuman food chain. The guidelines used in USDA's South Florida Dairy HerdDemonstration Program were:

Serological surveillance with a LAM-based Map ELISA test;

Fecal culture (elimination of significant shedders);

Clinical impression of disease; and

Significant decrease in milk and milk fat production.

This advocated approach is diseased focused and does not effectively usethe now perceived natural history of Map infection nor the utility ofdual surveillance within a Herd Management Schema to better identifyinfection with Map and determine the significance of a serological Maptiter.

The FUIDI Herd Management Schema utilizes:

a serological single or multi-organism prototoplasm-based test toidentify both current and past Map infection;

a LAM-based Map ELISA test to determine any degree of Map replication;

the fact that the majority of infected animals with low level andsuspicious levels of Map antibodies will achieve subsequent immunecapture to a varying degree;

the fact that 20-25% of animals with a diagnostic level of Mapantibodies may also achieve subsequent immune capture;

the fact that animals with recent immune capture at the time ofparturition may experience reactivation of infection; and

the fact that majority of animals who are low Map fecal shedders and areserologically negative will exhibit subsequent immune capture.

The novelty in the information and its sequential utilizationconstitutes the basis for the invention and its claim to being abusiness method utility patent.

TABLE 1 Comparison of FUIDI and PARACHEK Map ELISA tests PARACHEKComparison Source Cow# ELISA PARACHEK Dairy 1* 8384 2.62 Neg Dairy 18661 2.61 Neg Dairy 1 8369 2.19 Neg Dairy 1 3721 2.46 Neg Dairy 1 35342.9 Neg Dairy 1 8291 1.94 Neg Dairy 1 8244 3.6 Neg Dairy 1 8064 2.08 NegDairy 1 8673 3.25 Neg Dairy 1 3119 2.11 Neg Dairy 1 7301 1.56 Neg Dairy1 3238 1.46 Neg Dairy 1 6279 2.73 Neg Dairy 1 3815 1.65 Neg Dairy 1 88001.41 Neg Dairy 1 3361 1.22 Neg Dairy 1 2916 0.96 Neg Dairy 1 3405 1.4Neg Dairy 1 7345 0.88 Neg Dairy 1 7659 0.58 Neg Dairy 1 3201 1.29 NegDairy 1 7519 0.63 Neg Dairy 1 3870 0.92 Neg Dairy 1 3520 0.65 Neg Dairy1 7304 0.82 Neg Dairy 1 7658 0.61 Neg Dairy 1 3737 1.24 Neg Dairy 2* 281.72 Neg Dairy 2 93 4.5 Susp Dairy 2 125 2.79 Neg Dairy 2 306 2.43 NegDairy 2 329 2.03 Susp Dairy 2 358 3.48 Neg Dairy 2 458 4.22 Susp Dairy 2587 1.41 Neg Dairy 2 293 1.02 Neg Dairy 2 699 2.4 Neg Dairy 2 734 2.19Susp Dairy 2 837 1.8 Susp Dairy 2 839 2.07 Susp Dairy 2 1260 2.67 SuspDairy 2 1273 3.37 Susp Dairy 2 1514 6.57 Pos Dairy 2 1625 2.2 Neg Dairy2 1718 4.87 Susp Dairy 2 1733 2.92 Neg Dairy 2 1581 1.72 Neg Dairy 22020 1.4 Neg Dairy 2 2075 0.95 Pos Dairy 2 1995 3.76 Susp Dairy Herd#1 - reputedly Map-free Dairy Herd #2 - known to have a significant # ofsero-reactive cows FUIDI values - 1.5 = negative; 1.51-1.99 =suspicious; 2.0 and above = positive PARACHEK FUIDI Positive/ positive/Source inconclusive suspicious Dairy Herd #1 0/0 10/0 Dairy Herd #2 2/1016/3

TABLE 2 Comparison of PARACHEK ELISA Titers February 2008 with FUIDIELISA Titers on Sera with Pre-existing Map Antibodies PARACHEK Cow #Dec. 13, 2006 Feb. 28, 2008 FUIDI #1 1011 .08 2.38 2.5 2290 1.32 0.051.0 2484 0.72 0.02 1.6 2920 1.42 n.d. 3.6 3125 0.02 0 3.3 3297 0.04 03.4 3728 0.08 0 2.1 3731 0.03 0 1.2 3739 0.09 0 1.97 3925 0.08 .11 2.3n.d. = no data

TABLE 3 Comparative ELISA Titers between PARACHEK and FUIDI Map ELISATests in Sera with Newly Developed Map Antibodies PARACHEK Cow # Dec.13, 2006 Feb. 28, 2008 FUIDI #1 637 n.d. .06 3.1 1664 0 .06 1.9 2139 0.02 1.6 2393 0 .01 1.5 3111 0 .03 2.0 3485 0 .03 0.89 3523 0 .01 1.13783 0 .04 1.3 3790 0 .02 2.0 3811 0 .02 3.3 4259 n.d. .05 1.24 n.d. =no data

TABLE 4 Correlation of FUIDI-positive Sera with Prior PARACHEK ResultsPARACHECK Cow # Dec. 13, 2006 Feb. 28, 2008 FUIDI #1 FUIDI #1 Titer (2.5and greater) 128 0 0 2.6 637 n.d. 0.06 3.1 1011 0.08 2.38 2.5 2109 n.d 02.9 2761 n.d. 0 3.2 2920 1.42 n.d. 3.6 3107 0.2 0 3.3 3297 0.04 0 3.43387 n.d. 0.05 3.4 3536 n.d. 0 2.9 3811 0 0.02 3.3 3945 0 0.05 3.4 n.d.= no data

TABLE 5 Correlation of FUIDI-Positive and -Suspicious MAP ELISA Titerswith Any PARACHEK Titer PARACHEK Titer Cow # FUIDI ELISA #1 Dec. 13,2006 Feb. 28, 2008 FUIDI #1 Titer (2.5 and greater)  128 2.6 0 0  637*3.1 — 0.06 1011 2.5 0.08 2.38 1663 2.9 0 0 2109 2.9 0 2674 3.3 — — 27613.2 0 2920 3.6 1.42 — 3107 3.3 0.2 0 3160 2.6 0 0 3297 3.4 0.04 0 35362.9 0 0 3702 2.5 0 0 3811 3.3 0 0.02 3945 3.4 0 0.05 3387 3.1 — 0 43202.6 — 0 FUIDI #1 Titer (1.9-2.49)  480 2.3 n.d 1004 2.1 0 2676 2.3 02891 2.0 0 3103 2.0 0 3111 2.0 0.03 3611 2.12 0 3621 2.1 0 3652 1.9 03728 2.1 0.08 0 3735 2.3 0 3739 1.97 0.09 0 3763 2.1 0 3790 2.0 0.023925 2.3 0.08 0.11 3953 2.1 0 4115 1.9 0 4194 2.1 0.02 4212 1.9 0 43142.1 0 4471 2.3 0 n.d. = no data

TABLE 6 Correlation of PARACHEK and FUIDI Map ELISA Titers with PositiveFecal Cultures PARACHEK ELISA FUIDI ELISA #1 Cow # 2008 2008 Culture1011 2.38 (positive) 2.5 (positive) ls 3160 0 2.16 (suspicious) ms 41560 1.3 (negative) ls 4237 0 1.4 (negative) ls 3394 0 1.6 (negative) ms4101 0 1.1 (negative) ms 4115 0 1.9 (suspicious) ms 4194 0.02 2.1(suspicious) hs 4212 0 1.9 (suspicious) ms 4235 0 1.3 (negative) ls 42370.01 1.3 (negative) ms ls = light shedder ms = medium shedder hs = heavyshedder

REFERENCES

-   1. Stabel J. R.: Johne's disease: a hidden threat. J. Dairy Science    1998; 81:283-288-   2. Chi J., Van Leeuwen J. A., Weersink A., Keefe G. P.: Direct    production loses and treatment costs from bovine viral diarrhea    virus, bovine leucosis virus Mycobaterium avium subsp.    paratuberculosis and Neospora caninum. Prevent. Vet. Med. 2002;    69:2075-2082-   3. Eamens G J, Whittington R J, Marsh I B, Turner M J, Saunders V,    Kemsley P D, Rayward D: Comparative sensitivity of various fecal    culture methods and ELISA in dairy cattle herds with endemic Johne's    disease. Vet. Microbiol. 2000; 77:357-367-   4. Sweeney R W, Whitlock R H, Buckley C L, Spencer P A: Evaluation    of a commercial-linked enzyme immunosorbent assay for the diagnosis    of paratuberculosis. J. Vet. Diagn. Invest. 1995; 7:488-493-   5. Collins M. T., Wells S. J, Petrini K. R. et al.: Evaluation of    five antibody detection tests for the diagnosis of bovine    paratuberculosis. Clin. Diagn. Immunol. 2005; 12: 685-692-   6. Sockett D. C., Conrad T. A., Thomas C. B., Collins M. T.:    Evaluation of four serological tests for bovine paratuberculosis. J.    Clin. Microbiol. 1992; 30:1134-1139-   7. Sweeney R. W., Whitlock R. H., McAdams S., Fyock T.: Longitudinal    study of ELISA seroreactivity to Mycobaterium avium subspecies    paratuberculosis in infected cattle and culture-negative herd    mates. J. Vet. Diagn. Invest. 2006; 18:2-6-   8. McKenna S. L. B., Barkema H. W., Keefe G. P., Sockett D. C.:    Agreement between three Elisa's for Mycobaterium avium subsp.    paratuberculosis in dairy cattle. Vet. Microbiol. 2006; 31:285-291-   9. Cocito C., Gilot P., Coene M. de Kesel M., Poupart P., Vannuffel    P.: Paratuberculosis. Clin. Microbiol. Review 1994; 7:328-345-   10. Collins M. T., Wells S. J., Petrini K. R. Collins J E, Schultz R    D, Whitlock R H.: Evaluation of five antibody detection tests for    diagnosis of bovine paratuberculosis. Clin. Diagn. Immunol. 2005:    12:685-692-   11. Collins M. T., Gardner I. A., Garry F. B., Roussel A. J.,    Wells S. J.; Consensus recommendations on diagnostic testing for the    detection of paratuberculosis in cattle in the United States. J. Am.    Vet. Med. Assoc. 2006; 229:19121918-   12. Williams E., Monif, G. R. G., Buergelt C. D.: Comparative    analysis of different Map ELISA tests The Paratuberculosis    Newsletter March 2008:7-   13. Williams E., Monif G. R. G.: Comparative Map ELISA tests done on    cows with necropsy documented disease. The Paratuberculosis    Newsletter. March 2008: 7-8-   14. Harrell C. D., Gauthier J., Berman W.: Unpublished data.-   15. Herman-Taylor J., Bull T. J., Sheriden J. M.: Causation of    Crohns disease by Mycobaterium avium subspecies paratuberculosis.    Canadian J. Gastroenteriol. 2001; 14:521-527-   16. Whittington R., Marsh I., Chow E., Cousins D.: Polymorphism in    IS1311, an insertion sequence common to Mycobaterium avium subsp.    paratuberculosis, can be used to distinguish between and within    these species. Mol. Cell. Probes 1998; 12: 349-358-   17. England S., Bolske G., Johnansson: An IS900-like sequence found    in Mycobacterium sp. other than Mycobacterium avium subspecies    paratuberculosis. FEMS Microbiol. Lett. 2002; 34:734-737-   18. Tasara T., Hoelzle L. E., Stephan R.: Development and evaluation    of a Mycobaterium avium subspecies paratuberculosis (MAP) specific    multiplex PCR assay. Int. J. Food Microbiol 2005; 104:279-287-   19. Bolski G, Johansson K-F: An IS900-like sequence found in a    Mycobacterium sp. other than Mycobaterium avium subspecies    paratuberculosis. FEMS Microbiol. Lett. 2002; 209:267-271-   20. Cousins D. V., Whittington R., Marsh I. Masters R. J., Evans R.    J., Kluver P.: Mycobacteria distinct from Mycobaterium avium    subspecies paratuberculosis isolated from feces of ruminants posses    IS900-like sequences detectable by polymerase chain reaction:    implications for diagnosis. Mol. Cell. Probes 1999; 14:431-442.-   21. Coffin J. W. C., Condon C. A., Compston K. N. et al: Use of    restriction fragment length polymorphisms resolved by pulsed-field    gel electrophoresis for subspecies identification of mycobacteria in    the Mycobacterium avium-complex and for isolation of DNA probes. J.    Clin. Microbiol. 1992; 30:1829-1836,-   22. Makeda S., Turenne C. Y., Behr M. A.: Insertion Sequence IS900    revisited. J. Clin. Microbiol. 2006; 44:1081-1083-   23. Frdriksdottr V., Gunnarsson E., Sigurdarson G.,    Gudmundsdottir K. B.: Paratuberculosis in Iceland: epidemiology,    control measures past and present. IN Manning E. J. B. and    Collins M. T (Eds.) Proceedings of the Sixth Colloquium on    Paratuberclosis, 1999, Melbourne, Australia, February 14-18, pp.    105-108-   24. Whittington R. J., Targel C. A., Ottaway S., Marsh I., Seaman    J., Fridriksdottir V.: Molecular epidemiological confirmation and    circumstances of occurrence of sheep (S) strain of Mycobaterium    avium subsp. paratuberculosis in cases of paratuberculosis in cattle    in Australia and sheep and cattle in Iceland. Vet. Microbiol. 201;    79:311-32-   25. Osterstock J. B., Fosgate G. T., Norby, B. Manning E. J. B.    Collins M. T., Roussel A. J.: Contributions of environmental    mycobacteria to false-positive serum ELISA results for    paratuberculosis. J. Am. Vet. Med. Assoc. 2007; 230:896901-   26. Daley J, W, Monif, G. R. G. in Infectious Diseases in Obstetrics    and Gynecology. 6.sup.th edition 2008, Gilles R. G. Monif and David    Baker (Ed.s). Informa, Andover Hampshire, UK. pp 318-330-   27. Tizard I. R.: Acquired Immunity: Antigen-Presenting Receptors.    In Veterinary Immunology, Ian R. Tizard editor. 7^(th) edition, pp.    67-77. Elsevier, Philadelphia, Pa.-   28. Tizard I. R.: Acquired immunity to bacteria and related    organisms. In Veterinary Immunology, Ian R. Tizard editor. 7th    edition. Cheaper 23, pp. 273-276. Elsevier, Philadelphia, Pa.-   29. Ayele W. Y., Svastova P., Roubal P., Bartos M, Pavlik I.:    Mycobacterium avium subspecies paratuberculosis cultured from    locally and commercially pasteurized cow's milk in the Czech    Republic. Appl. Envir. Microbiol. 71:1210-1214, 2005-   30. Clarke C. J. The pathology and pathogenesis of paratuberculosis    in ruminants and other species. J. Comp. Pathol. 116:217-261, 1997-   31. Chiodini R. J., Van Kruiningen H. J., Merkal R. S.: Ruminant    paratuberculosis (Johne's disease): the current status and future    prospects. Cornell Vet. 74:218-262, 1984-   32. Chiodini R. J., Rossiter C. A.: Paratuberculosis: A potential    zoonosis.: Vet. Clin. North America: Food Animal Practices    12:457-467, 1996-   33. Ellingson J. L., Anderson J. L., Koziczkowski J. J., Radcliff R.    P., Sloan S. J., Allen S. E., Sullivan N. M.: Detection of viable    Mycobacterium avium subspecies paratuberculosis in retail    pasteurized whole milk by two culture methods and PCR. J. Food Prot.    68:966-972, 2005-   34. Giese S. B., Ahrens P.: Detection of Mycobaterium avium subsp.    paratuberculosis in milk from clinically affected cows by PCR and    culture. Vet. Microbiol. 77:291-297, 2000-   35. Grant I. R., Ball H. J., Rowe M. T.: Incidence of Mycobacterium    paratuberculosis in bulk raw and commercially pasteurized milk from    approved dairy processing establishments in the United Kingdom.    Appl. Envir. Microbiol. 68:2428-2435, 2002-   36. Grant I. R.: Zoonotic potential of Mycobaterium avium subsp.    paratuberculosis: the current problem. J. Appl. Microbiol.    98:1292-1290, 2005-   37. Hermon-Taylor J., Barnes N., Clarke C., Finlayson C.: Grand    Rounds Mycobacterium paratuberculosis cervical lymphadenitis,    followed five years later by terminal ileitis similar to Crohn's    disease. British Med. J.316b:449-453, 1998-   38. Millar D., Ford J., Sanderson J., Withey S., Tizard M., Doran    T., Hermon-Taylor J.: IS900 PCR to detect Mycobaterium avium    subspecies paratuberculosis in retail supplies of whole pasteurized    milk in England and Wales. Appl. Environ Microbiol. 62:3446-52, 1996-   39. Mishina D., Katsel P., Brown S. T. Gilberts C. A. M.,    Greenstein R. J.: On the etiology of Crohn's disease. Proc. Natl.    Acad. Sci. USA 93:9816-20, 1996-   40. Naser S. A., Schwartz D., Shafran I.: Isolation of Mycobaterium    avium subsp. paratuberculosis from breast milk of Crohn's disease    patients. Am. J. Gastroentereol; 95:1094-1095, 2000-   41. Naser S. A., Ghobrial G., Pomero C., Valentine J. F.: Culture of    Mycobacterium avium subspecies paratuberculosis from the blood of    patients with Crohn's disease. Lancet 364:1039-1044, 2004-   42. Ott S. L., Wells S. J., Wagner B. A.: Herd-level economic losses    associated with Johne's disease on US dairy operations. Prev. Vet.    Med. 40:179-192, 1999-   43. Raizman E. A., Wells S. J., Jordan P. A., DelGiudice G. D.,    Bey R. R.: Mycobaterium avium subsp. paratuberculosis from    free-ranging deer and rabbits surrounding Minnesota dairy herds.    Can. J. Vet. Res. 69:32-38, 2005-   44. Sechi L. A., Mura M., Tanda F. Amelia L, Antonello S, Fadda G,    and Zanetti S.: Identification of Mycobaterium avium subsp.    paratuberculosis in biopsy specimens from patents with Crohn's    disease. J. Clin. Microbiol. 39:4514-17, 2001-   45. Sechi L. A, Scanu A. M, Molicotti P, Cannas S, Mura M. Dettori    G, Fadda G, Zanetti S.: Detection and isolation of Mycobaterium    avium subspecies paratuberculosis from intestinal biopsies of    patients with and without Crohn's disease in Sardinia. Am. J.    Gastroenteriol. 100:1529-1536, 2005-   46. Whitlock R. H., Buergelt C. D.: Preclinical and clinical    manifestations of paratuberculosis (including pathology). Vet.    Clin. N. Am. 12:357-371, 1996-   47. Whittington R J, Hope A F, Marshall A. D.: Molecular    epidemiology of Mycobaterium avium subsp. paratuberculosis: IS900    restriction fragment length polymorphism and IS 1311 polymorphism    analysis from animals and a human in Australia J. Clin. Microbiol    38:3240-3248, 2000-   48. Wuhib Y. A., Svastova P., Roubal P., Artos M., Paylik I.:    Mycobacterium avium subspecies paratuberculosis cultured from    locally and commercially pasteurized cow's milk in the Czech    Republic. Appl. Environ Microbiol. 71:1210-1214, 2005-   49. Cocito C., Gilot P., Coene M. de Kesel M., Poupart P., Vannuffel    P.: Paratuberculosis. Clin. Microbiol. Review 1994; 7:328-345-   50. Collins M. T., Wells S. J, Petrini K. R. et al.: Evaluation of    five antibody detection tests for the diagnosis of bovine    paratuberculosis. Clin. Diagn. Immunol. 2005; 12: 685-692-   51. Harris N. B., Bareletta R. G.: Mycobaterium avium subsp.    paratuberculosis in Veterinary Medicine. Clin. Microbiol Reviews    2001; 14:489-512-   52. McKenna S. L. B., Barkema H. W., Keefe G. P., Sockett D. C.:    Agreement between three Elisa's for Mycobaterium avium subsp.    paratuberculosis in dairy cattle. Vet. Microbiol. 2006; 31:285-291-   53. Sockett D. C., Conrad T. A., Thomas C. B., Collins M. T.:    Evaluation of four serological tests for bovine paratuberculosis. J.    Clin. Microbiol. 1992; 30:1134-1139-   54. Sugden E. A., Stilwel K., Michaelides A.: A comparison of    lipoarabinomannan with other antigens used in the absorbed enzyme    immunoassay for serological detection of cattle infected with    Mycobacterium paratuberculosis. J. Vet. Diagn. Invest. 1997;    9:413-417-   55. Sweeney R. W., Whitlock R. H., 12. McAdams S., Fyock T.:    Longitudinal study of ELISA seroreactivity to Mycobaterium avium    subspecies paratuberculosis in infected cattle and culture-negative    herd mates. J. Vet. Diagn. Invest, 2006; 18:2-6-   56. Williams E., Monif G. R. G., Buergelt C. D.; Comparative    analysis of different Map ELISA tests. The Paratuberculosis    Newsletter. March 2008:9-10

1. A method of managing an animal herd comprising: a) identifying prioror current infection/disease in an animal caused by Mycobacterium aviumsubspecies paratuberculosis (MAP) and genomically related mycobacteriacomprising conducting an initial serological ELISA test to identifyintracellular antigens of MAP and genomically related mycobacteria, saidserological ELISA test comprising contacting serum from an animal withFUIDI antigen and detecting the binding of antibodies to said FUIDIantigen, said FUIDI antigen deposited as ATCC PTA-11837, said managingcomprising categorizing animals in said herd by designating an animal asbeing negative or positive for the presence of antibodies binding saidFUIDI antigen in said initial serological ELISA test; and b)administering a dietary supplement to an animal designated as beingpositive for the presence of antibodies binding said FUIDI antigen insaid initial serological ELISA test.
 2. The method according to claim 1,wherein an animal is retested annually if the serum from said animaldoes not contain detectable antibodies that bind said FUIDI antigen. 3.The method according to claim 1, further comprising conducting a secondserological ELISA test on animals categorized as positive by saidinitial serological ELISA test, said second serological ELISA testcomprising contacting a serum sample from said animal with MAP and/orrelated mycobacterium lipoarabinomannan polysaccharides and/or membranelipoproteins and detecting the binding of antibodies to said MAP orrelated mycobacterium lipoarabinomannan polysaccharides and/or membranelipoproteins.
 4. The method according to claim 3, wherein an animalwhose serum contains antibodies that bind to said MAP and/or relatedmycobacterium lipoarabinomannan polysaccharides and/or membranelipoproteins are re-tested every three months after said secondserological ELISA test to determine the presence or absence ofantibodies that bind to said MAP or related mycobacteriumlipoarabinomannan polysaccharides and/or membrane lipoproteins.
 5. Themethod according to claim 4, wherein an animal that tests negative forantibodies after an initial serological ELISA test is categorized ashaving had a prior Map infection and said animal is non-infectious. 6.The method according to claim 1, further comprising conducting a PCRassay on biological samples from an animal positive for the presence ofantibodies binding to FUIDI antigen to determine the presence or absenceof nucleic acids from MAP.
 7. The method according to claim 3, furthercomprising conducting a PCR assay on biological samples from an animalpositive for the presence of antibodies binding MAP and/or relatedmycobacterium lipoarabinomannan polysaccharides and/or membranelipoproteins to determine the presence or absence of nucleic acids fromMAP.
 8. The method according to claim 4, further comprising conducting aPCR assay on biological samples from an animal positive for the presenceof antibodies binding MAP and/or related mycobacterium lipoarabinomannanpolysaccharides and/or membrane lipoproteins to determine the presenceor absence of nucleic acids from MAP.